In most Alzheimer's clinical trials, joining the placebo group doesn't mean giving up treatment. Participants usually keep taking their approved Alzheimer's medicines, and the study drug or a placebo is added on top of that usual care.
A placebo is an inactive look-alike treatment. It lets researchers tell whether changes come from the new drug or from something else. Because both groups stay on their usual care, the comparison is fair and no one is left without the treatment they already had.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Do Placebo Participants Keep Their Alzheimer's Medications?
- How an Add-On Trial Works
- Why Researchers Still Use a Placebo
- The Rules That Come With Usual Care
- What to Ask Before Enrolling
- Frequently Asked Questions
Do Placebo Participants Keep Their Alzheimer's Medications?
In most cases, yes. The Alzheimer's Association's statement on placebo controls says most US Alzheimer's trials use a placebo group and let participants continue their FDA-approved Alzheimer's medications. That holds whether a person gets the placebo or the study drug. Eli Lilly's donanemab trial is a good example.
Lilly's TRAILBLAZER-ALZ protocol let both groups take symptom drugs such as cholinesterase inhibitors or memantine. The trial compared the study drug plus standard care against placebo plus standard care. Allergan's AGN-242071 study worked the same way. Participants with mild to moderate Alzheimer's stayed on donepezil, with or without memantine. The study drug or a placebo was then added.
How an Add-On Trial Works
This design is called an add-on study. The FDA's E10 guidance on control groups describes it as a trial where the new treatment and the placebo are each added to the same standard therapy.
Think of it as two groups on the same starting line: Any difference between the groups can then be credited to the study drug. The FDA also names add-on designs as a fitting use of placebo in its 2019 guidance on cancer trials, so the approach is used well beyond dementia research.
- Group A: usual Alzheimer's medicines plus the study drug
- Group B: usual Alzheimer's medicines plus a placebo
Why Researchers Still Use a Placebo
Ethics rules shape this choice. Under the Declaration of Helsinki, a new treatment should normally be tested against the best proven one. A placebo is allowed when no proven treatment exists, or when there is a strong scientific reason and no added risk of serious or irreversible harm. Keeping everyone on usual care helps a trial meet that standard.
Boehringer Ingelheim used this reasoning for its BI 409306 trial. It kept all patients on their usual Alzheimer's drugs because no disease-modifying treatment was available when the trial was designed. That context has since changed. Two anti-amyloid drugs, lecanemab and donanemab, are now approved. Older protocols written before those approvals may not reflect how new trials weigh placebo use today.
The Rules That Come With Usual Care
Continuing your medicines usually comes with conditions. In the TRAILBLAZER-ALZ protocol, background Alzheimer's drugs could continue only if they were standard care in the patient's country. The dose also had to be stable for at least 2 months before joining.
Dose changes during that trial required telling the sponsor. They were allowed only when needed for the patient's care. Stable doses matter because a medication change mid-study could blur the results.
What to Ask Before Enrolling
Allowing usual care is common, but not universal. Each trial's protocol sets which medicines are allowed, and some may require stable doses or exclude certain drugs.
Before signing up, ask the study team: Bring a full, current medication list to the screening visit, including supplements. The study team checks it against the trial's eligibility and medication rules.
- Can I keep taking every medication I use now, including non-Alzheimer's drugs?
- How long must my doses be stable before I start?
- What happens if my doctor needs to change a dose during the study?
- Are any drugs, including newer approved anti-amyloid treatments, excluded?
- Who should I tell if a new medication is prescribed?
Frequently Asked Questions
Will I know whether I'm getting the placebo?
Placebo-controlled trials are usually designed so participants can't tell which one they get, since knowing could affect the results.
Should I stop my current Alzheimer's medicine to qualify for a trial?
No, not on your own. Talk with the study team and your doctor first, because many trials require stable doses of the medicines you already take.
